Paul DiCorleto, PhD

Paul DiCorleto, Ph.D.

Appointed: 1982

No Patient Satisfaction Reviews
Paul DiCorleto, PhD
Department: Lerner Research Institute
Institute Chair
Location: Cleveland Clinic Main Campus
Mail Code NB21
9500 Euclid Avenue
Cleveland, OH 44195
Paul DiCorleto, PhD
Department: Cardiovascular Medicine
Location: Cleveland Clinic Main Campus
Mail Code NB21
9500 Euclid Avenue
Cleveland, OH 44195
Paul DiCorleto, PhD
Department: Cellular and Molecular Medicine
Location: Cleveland Clinic Main Campus
Mail Code NB21
9500 Euclid Avenue
Cleveland, OH 44195
Type of Doctor:

Biographical Sketch

Vascular Endothelial Cell Gene Expression Linked to Atherosclerosis and Other Inflammatory Diseases.

Current program:
  • Endothelial Cell Expression of Leukocyte Adhesion Molecules
  • TNF Activation of the Endothelium
  • Unni Chandrasekharan, PhD, Project Scientist
  • Daniel Harris, PhD, Doctoral Student (CWRU Physiology) 
  • Chad Bradley, Technician


  • Mohammad Rajabi, MD, PhD
  • Paul Fox, PhD
  • Thomas Egelhoff, PhD
  • Xiaoxia Li, PhD
  • Tatiana Byzova, PhD
  • Sathyamangla Prasad, PhD
Brief Description:

The central objective of our research is to understand the role of endothelial cell (EC) gene expression in the maintenance of healthy blood vessels and in the genesis of vascular diseases. We are pursuing the thrombin- and cytokine-activated intracellular signaling pathways and transcription factors responsible for induction of pro-inflammatory events, including leukocyte adhesion to EC, in vivo and in vitro. We are currently focused on the relative importance of the two tumor necrosis factor (TNF)-alpha receptors in EC activation and in such diseases as atherosclerosis and psoriasis. We are elucidating the specific signaling pathways triggered by each receptor that must combine to generate the inflammatory response. We are also studying the role of the homeobox transcription factor HOXA9 and its binding partner protein arginine methyl transferase 5 (PRMT5) in the induction of proinflammatory genes in EC. Finally, we are characterizing regulatory pathways involved in the expression of inflammatory genes and induction of angiogenesis by EC in response to the protease thrombin and the angiogenic factor VEGF and defining the induction and functions of the dual-specificity nuclear phosphatase MKP 1 (MAP kinase phosphatase-1). An overriding goal of the research program is to identify novel targets for anti-inflammation therapy.

Professional Highlights

  • Institute Chairman, Lerner Research Institute, Cleveland Clinic, Sherwin-Page Endowed Chair in Biomedical Research, 2002-Present
  • Chairman, Department of Molecular Medicine, Case School of Medicine, Case Western Reserve University, 2003-Present
  • Chairman, Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Jan Bleeksma Endowed Chair in Vascular Biology, 1989-2002
  • Associate Chief of Staff, Cleveland Clinic, 1997-2001
  • Vice Chairman, Lerner Research Institute, Cleveland Clinic, 1996-1999

Education & Fellowships

Doctorate - Cornell University
Ithaca, NY USA
Undergraduate - Rensselaer Polytechnic Institute
Troy, NY USA

Specialty Interests

endothelium, cell growth control, vascular cell interactions

Awards & Honors

  • Fellow, American Association for the Achievement of Science, 2007
  • Distinguished Achievement Award in Basic Science, Cleveland Clinic, 2004
  • President, North American Vascular Biology Organization, 2002-2003
  • Special Recognition Award of the AVTB Council, American Heart Association, 2001
  • Member, Advisory Panel on Research, Association of American Medical Colleges, 1999-Present
  • Member, Heart, Lung and Blood Program Project Review Committee, NHLBI, 1995-1999
  • Member, Board of Governors, Cleveland Clinic, 1990-1995
  • Visiting Scholar of the British Heart Fund, 1991
  • NIH Cellular Biology and Physiology Study Section -- member, 1987-1991; chairman, 1990-1991
  • Founding Co-Chair, Gordon Research Conference on Vascular Cell Biology, 1988
  • NIH Research Center Career Development Award, 1985-1990
  • DuPont Graduate Teaching Award, 1976
  • Merck Chemistry Award and the American Institute of Chemists Award, 1973
  • Rensselaer Medal Scholar, 1969-1973
  • Community Board Member, Cleveland State University Board of Trustees, 2008-present
  • Member, Board of Governors, National Center for Regenerative Medicine, Case Western Reserve University School of Medicine, 2011-present
  • Member, Governance Board, Cleveland Center for Membrane and Structural Biology, Case Western Reserve University School of Medicine, 2012-2014
  • Member, Board of Directors, Cleveland State University Research Corporation, 2012-present
  • Member, Research Advisory Committee, The Holden Arboretum, Kirkland, OH, 2013-present
  • Member, Board of Directors, The Holden Arboretum, Kirkland, OH, 2014-present


American Association for the Advancement of Science

  • Fellow, 2007

American Heart Association

  • Fellow of the Council on Arteriosclerosis Executive Committee, 1992-1994
  • Fellow of the Council on Arteriosclerosis, Thrombosis, and Vascular Biology, Program Committee, 1997-2001
  • Spring Conference Chair, 2000-2001
  • Executive Committee, 1998-2003
  • Research Steering Committee, 2005-2009

American Society for Cell Biology

American Society of Investigative Pathology

  • Program Committee, 1992-1997
  • Nominating Committee, 1998-2000

American Society for Microbiology

North American Vascular Biology Organization

  • Program Committee Chair, Council Member, 1995-2001
  • President-Elect, 2001-2002
  • President, 2002-2003
  • Scientific Advisory Board, October 2007 to October 2012

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 4/1/2015, Dr. DiCorleto has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English